Bone Sarcoma Clinical Trials

11 recruiting

Bone Sarcoma Trials at a Glance

15 actively recruiting trials for bone sarcoma are listed on ClinicalTrialsFinder across 6 cities in 28 countries. The largest study group is Not Applicable with 3 trials, with the heaviest enrollment activity in Houston, Rochester, and Bordeaux. Lead sponsors running bone sarcoma studies include Mayo Clinic, M.D. Anderson Cancer Center, and Centre Leon Berard.

Browse bone sarcoma trials by phase

Treatments under study

About Bone Sarcoma Clinical Trials

Looking for clinical trials for Bone Sarcoma? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Bone Sarcoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Bone Sarcoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 115 of 15 trials

Recruiting

Financial Toxicity in Patients With Resected Soft Tissue and Bone Sarcomas

Financial ToxicityBone Sarcomas
M.D. Anderson Cancer Center100 enrolled1 locationNCT07215611
Recruiting

Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas

OsteosarcomaChondrosarcomaBone Sarcoma+3 more
Memorial Sloan Kettering Cancer Center300 enrolled5 locationsNCT03442465
Recruiting
Phase 1Phase 2

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

Resectable SarcomaMetastatic Malignant Neoplasm in the LungMetastatic Bone Sarcoma+2 more
Roswell Park Cancer Institute99 enrolled1 locationNCT03965234
Recruiting
Not Applicable

Assessment of the Functional Outcome and Quality of Life in Sarcoma Patients

Soft Tissue SarcomaBone Sarcoma
Universitaire Ziekenhuizen KU Leuven60 enrolled1 locationNCT05051059
Recruiting

Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone

ChondrosarcomaBone SarcomaChordoma+2 more
Mayo Clinic72 enrolled3 locationsNCT05033288
Recruiting
Phase 2

A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)

Bone Sarcomas
M.D. Anderson Cancer Center70 enrolled1 locationNCT07193550
Recruiting
Not Applicable

Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas

AngiosarcomaOsteosarcomaEwing Sarcoma+4 more
Centre Leon Berard168 enrolled16 locationsNCT04055220
Recruiting
Phase 2

Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients

OsteosarcomaBone Sarcoma
Centre Leon Berard36 enrolled16 locationsNCT04698785
Recruiting

Evaluation of Tumor Resection Guided by Intraoperative Indocyanine Green Dye Fluorescence Angiography in Patients With Sarcoma

Soft Tissue SarcomaBone Sarcoma
Mayo Clinic50 enrolled1 locationNCT06409013
Recruiting

Biomarkers of Resiliency In Childhood Cancer Surgery

SarcomaNeuroblastomaPediatric Cancer+10 more
Mayo Clinic40 enrolled1 locationNCT06674811
Recruiting
Phase 1

In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma

Soft Tissue SarcomaBone SarcomaPulmonary Metastases
University Health Network, Toronto17 enrolled1 locationNCT02811523
Recruiting
Phase 1

A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma

Soft Tissue SarcomaBone Sarcoma
M.D. Anderson Cancer Center40 enrolled1 locationNCT05621668
Recruiting
Not Applicable

Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With Sarcoma

Soft Tissue SarcomaSarcomaBone Sarcoma
Memorial Sloan Kettering Cancer Center60 enrolled8 locationsNCT06129903
Recruiting
Phase 3

Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas

Bone SarcomaEmbryonal RhabdomyosarcomaAlveolar Rhabdomyosarcoma
N.N. Petrov National Medical Research Center of Oncology40 enrolled1 locationNCT06669013
Recruiting
Phase 3

A Pivotal Trial to Determine the Efficacy and Safety of AP23573 when Administered as Maintenance Therapy to Patients with Metastatic Soft Tissue or Bone Sarcomas.

Metastatic soft tissue or bone sarcomas
ARIAD Pharmaceuticals, Inc.650 enrolled26 locationsACTRN12608000214336